Intercure Ltd. Ordinary Shares
INCRIntercure Ltd. (INCR) is a biotech company focused on the development and commercialization of cannabis-based products and therapies. It operates through its subsidiaries, engaging in research, cultivation, extraction, and distribution within the medical cannabis industry. The company aims to provide high-quality medicinal cannabis solutions, leveraging innovative formulations to address various health conditions.
Company News
InterCure Ltd. announced a binding term sheet for NIS 22 million (approximately US$7.4 million) in private placement financing, with potential to increase to NIS 54 million. The funding includes investments from CEO Alexander Rabinovich and leading pharma-focused hedge funds including Bennu Pharma Fund Ltd. The company plans to use proceeds for g...
InterCure Ltd. (Nasdaq: INCR) received a notice from Nasdaq on February 25, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has been granted a 180-calendar day compliance period until August 24, 2026, to regain compliance. InterCure plans to consider a reverse share split as part of its strat...
InterCure reported preliminary 2025 revenue of NIS 265 million, representing 11% growth year-over-year with nearly 20% growth in H2 2025. The company achieved its twelfth consecutive half-year of positive Adjusted EBITDA and generated first significant revenues from the German market. The company also announced strategic acquisitions of Botanico ...
InterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI), gaining access to advanced AI-driven cultivation technologies and exclusive US cannabis brand partnerships, positioning itself for potential industry expansion amid potential cannabis rescheduling.
InterCure reported revenue of NIS 126 million and adjusted EBITDA of NIS 21 million for the first half of 2024. The company's southern facility was affected by a terrorist attack and the war in Gaza, but it is entitled to compensation from the Israeli authorities. InterCure plans to expand its partnership with Cookies and launch products in Germa...
